1
|
Herrán-Fonseca C, Jekov L, Persaud C, Alabbas F. Single vs Double-Unit Transfusion in Patients With Hematological Disorders Undergoing Chemotherapy or Stem Cell Transplantation: A Systematic Review And Meta-Analysis. Transfus Med Rev 2025; 39:150862. [PMID: 39537493 DOI: 10.1016/j.tmrv.2024.150862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2024] [Revised: 09/22/2024] [Accepted: 09/25/2024] [Indexed: 11/16/2024]
Abstract
There is no consensus to support the single unit-transfusion policy (1-RBC) over the double-unit transfusion policy (2-RBC) in patients with hematological disorders undergoing chemotherapy or stem cell transplantation. We searched PubMed, Embase, and Cochrane Library. Risk ratios (RR) and mean differences (MD) were pooled. Statistical analysis was performed using Review Manager and R software. Heterogeneity was assessed using I2 statistics. Hemoglobin (Hb) levels at discharge (MD -0.41 g/dL; 95% CI -0.53, -0.29 g/dL; P < .01) and total RBC units used per admission (MD -0.82 units; 95% CI -1.60, -0.05 units; P = .04) were significantly lower in patients who received 1-RBC, while length of hospital stay (MD 0.05 days; 95% CI -0.29, 0.39 days; P = .89), severe bleeding (RR 1.52; 95% CI 0.85, 2.71; P = .16) and mortality (RR 0.89; 95% CI 0.52, 1.53; P = .69) showed no significant difference between groups. In patients with hematological disorders undergoing chemotherapy or stem cell transplantation, 1-RBC is associated with lower Hb levels at discharge and a reduction in the total number of RBC units used per admission, with no significant difference in terms of length of hospital stay, severe bleeding risk, transfusion-related adverse events and mortality.
Collapse
Affiliation(s)
- Catalina Herrán-Fonseca
- Department of Medicine, Faculty of Health Sciences, Universidad Autónoma de Bucaramanga, Floridablanca, Colombia.
| | - Laura Jekov
- Faculty of Medicine and Psychology, Universidad Autónoma de Baja California, Tijuana, México
| | - Carlotta Persaud
- University Hospital of the West Indies, Internal Medicine, Faculty of Medical Sciences, Mona, Kingston, Jamaica
| | - Fahad Alabbas
- Scientific Research Center and Department of Pediatric Hematology and Oncology, Prince Sultan Medical, Military City, Riyadh, Saudi Arabia
| |
Collapse
|
2
|
Marco-Ayala J, Asensi Cantó P, Suarez M, Lamas B, Santiago M, Gómez I, Arnao M, Sanz J, Montava A, Sanz MÁ, de la Rubia J, Solves P. Single-Unit Transfusion Policy in Autologous Hematopoietic Stem Cell Transplantation: Less is Not Worse. Transfus Med Rev 2024; 38:150859. [PMID: 39383656 DOI: 10.1016/j.tmrv.2024.150859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 08/30/2024] [Accepted: 09/02/2024] [Indexed: 10/11/2024]
Abstract
Single-unit red blood cell (1-RBC) transfusion policy has shown to effectively reduce transfusion burden while maintaining comparable clinical outcomes in hematological patients compared to the classical double-unit policy. However, its effects specifically after autologous stem cell transplantation (ASCT) have not been previously studied. We aimed to evaluate the impact of the 1-RBC policy on transfusion burden in a homogeneous cohort of patients undergoing ASCT. We retrospectively compared the transfusion requirements and the clinical outcomes of 187 patients transplanted from May 2019 to December 2022 under a 1-RBC policy, with a historical cohort of 153 patients transplanted from January 2016 to April 2019 under a double-unit policy. The 1-RBC policy was associated with a 32% reduction in RBC utilization and lower number of RBC transfusions at day 30 after transplantation (median 2 versus 3 units; P < .0001), with an odds ratio of 0.49 in multivariate analysis (P = .03). However, the number of transfusion episodes remained similar (median of 2 in both arms; P = .34). No significant differences in length of stay, hemoglobin levels at discharge or 30-day mortality were observed. In conclusion, transitioning to the 1-RBC represents a straightforward action in current practice that significantly reduces blood transfusions in patients undergoing ASCT, without negatively impacting clinical outcomes.
Collapse
Affiliation(s)
- Javier Marco-Ayala
- Hematology Department, University Hospital Morales Meseguer, Murcia, Spain; Department of Medicine, University of Murcia, Murcia, Spain.
| | - Pedro Asensi Cantó
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Marina Suarez
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Brais Lamas
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Marta Santiago
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Inés Gómez
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain
| | - Mario Arnao
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Jaime Sanz
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain; Department of Medicine, University of Valencia, València, Spain
| | - Alberto Montava
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Miguel Ángel Sanz
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Department of Medicine, University of Valencia, València, Spain
| | - Javier de la Rubia
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain; Faculty of Medicine, Catholic University "San Vicente Mártir," Valencia, Spain
| | - Pilar Solves
- Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto Carlos III, Madrid, Spain
| |
Collapse
|
3
|
Solves P, Marco-Ayala J, Sanz MÁ, Gómez-Seguí I, Balaguer-Roselló A, Facal A, Villalba M, Montoro J, Sanz G, de la Rubia J, Sanz J. Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution. J Clin Med 2023; 12:jcm12103467. [PMID: 37240573 DOI: 10.3390/jcm12103467] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 05/09/2023] [Accepted: 05/10/2023] [Indexed: 05/28/2023] Open
Abstract
INTRODUCTION Transfusion plays a main role in supportive treatment for patients who receive an allogeneic hematopoietic stem cell transplantation (HSCT). In this study, we compare the transfusion requirements of patients undergoing different modalities of HSCT according to different time periods. The objective is to assess the evolution of HSCT transfusion requirements over time, from a single institution. METHODS The clinical charts and transfusion records of patients who underwent HSCT of different modalities at La Fe University Hospital during a twelve-year period were reviewed (2009-2020). For analysis, we divided the overall time into three periods: 1 from 2009 to 2012, 2 from 2013 to 2016 and 3 from 2017 to 2020. The study included 855 consecutive adult HSCT: 358 HLA-matched related donors (MRD), 134 HLA-matched unrelated donors (MUD), 223 umbilical cord blood transplantation (UCBT) and 140 haploidentical transplants (Haplo-HSCT). RESULTS There were no significant differences in RBC and PLT requirements or transfusion independence among the three time periods for MUD and Haplo-HSCT. However, the transfusion burden increased significantly for MRD HSCT during the 2017-2020 period. CONCLUSION despite HSCT modalities having evolved and changed over time, overall transfusion requirements have not significantly decreased and continue to be a cornerstone of transplantation-supportive care.
Collapse
Affiliation(s)
- Pilar Solves
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Javier Marco-Ayala
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Haematology Department, University Hospital "Morales Meseguer", 30007 Murcia, Spain
| | - Miguel Ángel Sanz
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Inés Gómez-Seguí
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Aitana Balaguer-Roselló
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Ana Facal
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
| | - Marta Villalba
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
| | - Juan Montoro
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Guillermo Sanz
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| | - Javier de la Rubia
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
- School of Medicine and Dentistry, Catholic University of Valencia, 46010 Valencia, Spain
| | - Jaime Sanz
- Haematology Department, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
- Centro de Investigación Biomédica en red Cancer, Instituto Carlos III, 28029 Madrid, Spain
| |
Collapse
|
4
|
Shih AW, Liu A, Elsharawi R, Crowther MA, Cook RJ, Heddle NM. Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion 2018; 58:2841-2860. [DOI: 10.1111/trf.14952] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2018] [Revised: 07/27/2018] [Accepted: 08/01/2018] [Indexed: 01/28/2023]
Affiliation(s)
- Andrew W. Shih
- Department of Pathology and Laboratory Medicine; University of British Columbia; Vancouver British Columbia Canada
- Department of Pathology, Vancouver Coastal Health Authority; Vancouver British Columbia Canada
| | - Aixin Liu
- Department of Medicine; Queens University; Kingston Ontario Canada
| | - Radwa Elsharawi
- Department of Medicine, School of Medicine; Wayne State University; Detroit Michigan
| | - Mark A. Crowther
- Department of Medicine; McMaster University; Hamilton Ontario Canada
| | - Richard J. Cook
- Department of Health Research, Methods and Impact; McMaster University; Hamilton Ontario Canada
- McMaster Centre for Transfusion Research; McMaster University; Hamilton Ontario Canada
| | - Nancy M. Heddle
- Department of Medicine; McMaster University; Hamilton Ontario Canada
- McMaster Centre for Transfusion Research; McMaster University; Hamilton Ontario Canada
| |
Collapse
|
5
|
Rahimi-Levene N, Ziv-Baran T, Peer V, Golik A, Kornberg A, Zeidenstein R, Koren-Michowitz M. Hemoglobin transfusion trigger in an internal medicine department - A "real world" six year experience. PLoS One 2018. [PMID: 29513750 PMCID: PMC5841806 DOI: 10.1371/journal.pone.0193873] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Transfusion guidelines advocate restrictive rather than liberal use of red blood cells (RBC) and are based mostly on randomized trials in intensive care and surgical departments. We aimed to study RBC transfusion practice in the medical patients' population. METHODS The data in this study were collected from patients over the age of 18 years admitted to an Internal Medicine department between 2009 and 2014 who received at least one unit of packed red blood cells (RBC). In addition, data on demographics, patients' diagnoses, laboratory tests and number of transfused RBC units were extracted from the electronic health records. RESULTS One thousand three hundred and twenty eight patients were included, having mean age of 75 ± 14 years. The median hemoglobin (Hb) trigger for RBC transfusion was 8.0 g/dl (IQR 7.3-8.7g/dl), and most patients received either one (43.4%) or two (33.4%) RBC units. There was no significant difference in Hb trigger between males and females (Hb 8.0 g/dl and 7.9 g/dl, respectively, p = 0.098), and a weak correlation with age (r = 0.108 p = 0.001). Patients with cardiovascular and lung diseases had a statistically significant higher Hb trigger compared to patients without those diagnoses, however the median difference between them was 0.5 g/dl or less. CONCLUSIONS These "real world" data we collected show a Hb trigger compliant with the upper limit of published guidelines and influenced by medical patients' common diagnoses. Prospective trials addressing patients hospitalized in internal medicine departments could further contribute to transfusion decision algorithms.
Collapse
Affiliation(s)
- Naomi Rahimi-Levene
- Blood Bank, Assaf Harofeh Medical Center, Zerifin, Israel
- Hematology Institute, Assaf Harofeh Medical Center, Zerifin, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- * E-mail: (NRL); (MKM)
| | - Tomer Ziv-Baran
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Victoria Peer
- Blood Bank, Assaf Harofeh Medical Center, Zerifin, Israel
| | - Ahuva Golik
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Internal Medicine Department A, Assaf Harofeh Medical Center, Zerifin, Israel
| | - Abraham Kornberg
- Hematology Institute, Assaf Harofeh Medical Center, Zerifin, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ronit Zeidenstein
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Internal Medicine Department A, Assaf Harofeh Medical Center, Zerifin, Israel
| | - Maya Koren-Michowitz
- Hematology Institute, Assaf Harofeh Medical Center, Zerifin, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- * E-mail: (NRL); (MKM)
| |
Collapse
|